121 related articles for article (PubMed ID: 33517319)
1. Clinical Applicability of the Proliferation Marker Thymidine Kinase 1 in Head and Neck Cancer Patients.
Meirovitz A; Gross M; Leibovici V; Sheva K; Popovzer A; Barak V
Anticancer Res; 2021 Feb; 41(2):1083-1087. PubMed ID: 33517319
[TBL] [Abstract][Full Text] [Related]
2. Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.
Wang J; Liu Q; Zhou X; He Y; Guo Q; Shi Q; Eriksson S; Zhou J; He E; Skog S
Tumour Biol; 2017 Jun; 39(6):1010428317706479. PubMed ID: 28651488
[TBL] [Abstract][Full Text] [Related]
3. Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma.
Wu BJ; Li WP; Qian C; Ding W; Zhou ZW; Jiang H
Tumour Biol; 2013 Apr; 34(2):643-8. PubMed ID: 23179401
[TBL] [Abstract][Full Text] [Related]
4. Serum thymidine kinase 1 activity in breast cancer.
Nisman B; Allweis T; Kaduri L; Maly B; Gronowitz S; Hamburger T; Peretz T
Cancer Biomark; 2010; 7(2):65-72. PubMed ID: 21178264
[TBL] [Abstract][Full Text] [Related]
5. Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes.
Wang Z; Zhang W; Huo B; Dong L; Zhang J
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32202305
[TBL] [Abstract][Full Text] [Related]
6. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
[TBL] [Abstract][Full Text] [Related]
7. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.
Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V
Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555
[TBL] [Abstract][Full Text] [Related]
8. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
[TBL] [Abstract][Full Text] [Related]
9. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
10. A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.
Kumar JK; Aronsson AC; Pilko G; Zupan M; Kumer K; Fabjan T; Osredkar J; Eriksson S
Tumour Biol; 2016 Sep; 37(9):11937-11945. PubMed ID: 27079872
[TBL] [Abstract][Full Text] [Related]
11. Serum detection of thymidine kinase 1 as a means of early detection of lung cancer.
Alegre MM; Weyant MJ; Bennett DT; Yu JA; Ramsden MK; Elnaggar A; Robison RA; O'Neill KL
Anticancer Res; 2014 May; 34(5):2145-51. PubMed ID: 24778016
[TBL] [Abstract][Full Text] [Related]
12. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma.
He E; Xu XH; Guan H; Chen Y; Chen ZH; Pan ZL; Tang LL; Hu GZ; Li Y; Zhang M; Zhou J; Eriksson S; Fornander T; Skog S
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):352-8. PubMed ID: 20544519
[TBL] [Abstract][Full Text] [Related]
13. Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas.
Jaamaa S; Nevala R; Jagarlamudi K; Tukiainen E; Blomqvist C; Sampo M
Anticancer Res; 2022 Mar; 42(3):1509-1515. PubMed ID: 35220246
[TBL] [Abstract][Full Text] [Related]
14. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients.
Nisman B; Allweis T; Kadouri L; Mali B; Hamburger T; Baras M; Gronowitz S; Peretz T
Clin Chem Lab Med; 2013 Feb; 51(2):439-47. PubMed ID: 23093267
[TBL] [Abstract][Full Text] [Related]
15. Expression and Clinical Significance of Cytokeratin-19 and Thymidine Kinase-1 in Advanced Gastrointestinal Cancer.
Du YY; Zhang QJ; Sun GP
Chin Med J (Engl); 2016 Sep; 129(18):2168-72. PubMed ID: 27625087
[TBL] [Abstract][Full Text] [Related]
16. Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker.
Jagarlamudi KK; Westberg S; Rönnberg H; Eriksson S
BMC Vet Res; 2014 Oct; 10():228. PubMed ID: 25293656
[TBL] [Abstract][Full Text] [Related]
17. A New Sandwich ELISA for Quantification of Thymidine Kinase 1 Protein Levels in Sera from Dogs with Different Malignancies Can Aid in Disease Management.
Jagarlamudi KK; Moreau L; Westberg S; Rönnberg H; Eriksson S
PLoS One; 2015; 10(9):e0137871. PubMed ID: 26366881
[TBL] [Abstract][Full Text] [Related]
18. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer.
Li HX; Lei DS; Wang XQ; Skog S; He Q
Oncol Rep; 2005 Jan; 13(1):145-9. PubMed ID: 15583816
[TBL] [Abstract][Full Text] [Related]
19. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.
He Q; Fornander T; Johansson H; Johansson U; Hu GZ; Rutqvist LE; Skog S
Anticancer Res; 2006; 26(6C):4753-9. PubMed ID: 17214336
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.
He Q; Zou L; Zhang PA; Lui JX; Skog S; Fornander T
Int J Biol Markers; 2000; 15(2):139-46. PubMed ID: 10883887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
